Zosano Pharma (NASDAQ:ZSAN) has completed the last portion of the long-term safety study of migraine candidate Qtrypta (zolmitriptan). More than 50 patients at 31 U.S. sites were followed for a year.
The rate of pain freedom at two hours following the application of the patch was ~44% while the rate of freedom from the most bothersome symptom was 68% and pain relief 81%. The safety profile was favorable as was long-term tolerability.
The company expects to file a U.S. marketing application in Q4.
Update: Shares are up 23% in early trade.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.